SG11201705727TA - 9h-pyrrolo-dipyridine derivatives - Google Patents
9h-pyrrolo-dipyridine derivativesInfo
- Publication number
- SG11201705727TA SG11201705727TA SG11201705727TA SG11201705727TA SG11201705727TA SG 11201705727T A SG11201705727T A SG 11201705727TA SG 11201705727T A SG11201705727T A SG 11201705727TA SG 11201705727T A SG11201705727T A SG 11201705727TA SG 11201705727T A SG11201705727T A SG 11201705727TA
- Authority
- SG
- Singapore
- Prior art keywords
- pyrrolo
- dipyridine
- derivatives
- dipyridine derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0463—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15153448 | 2015-02-02 | ||
| PCT/EP2016/051993 WO2016124508A1 (en) | 2015-02-02 | 2016-01-29 | 9h-pyrrolo-dipyridine derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201705727TA true SG11201705727TA (en) | 2017-08-30 |
Family
ID=52477553
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201705727TA SG11201705727TA (en) | 2015-02-02 | 2016-01-29 | 9h-pyrrolo-dipyridine derivatives |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US20180022748A1 (enExample) |
| EP (1) | EP3253762B1 (enExample) |
| JP (1) | JP6579670B2 (enExample) |
| KR (1) | KR102621513B1 (enExample) |
| CN (1) | CN107207508B (enExample) |
| AU (1) | AU2016214537B2 (enExample) |
| BR (1) | BR112017016311A2 (enExample) |
| CA (1) | CA2973648C (enExample) |
| CL (1) | CL2017001923A1 (enExample) |
| DK (1) | DK3253762T3 (enExample) |
| EA (1) | EA036518B1 (enExample) |
| ES (1) | ES2875734T3 (enExample) |
| IL (1) | IL253381B (enExample) |
| MX (1) | MX378155B (enExample) |
| MY (1) | MY191590A (enExample) |
| SG (1) | SG11201705727TA (enExample) |
| WO (1) | WO2016124508A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2247558T4 (da) | 2008-02-14 | 2024-07-29 | Lilly Co Eli | Nye billeddannelsesmidler til detektering af neurologisk dysfunktion |
| EP3253762B1 (en) * | 2015-02-02 | 2021-05-05 | UCB Biopharma SRL | 9h-pyrrolo-dipyridine derivatives |
| KR102472003B1 (ko) * | 2016-07-22 | 2022-11-29 | 에이씨 이뮨 에스에이 | 타우 단백질 응집체를 이미징하기 위한 화합물 |
| US10865207B2 (en) | 2016-07-22 | 2020-12-15 | Ac Immune S.A. | Compounds for imaging Tau protein aggregates |
| JP6997769B2 (ja) * | 2016-09-09 | 2022-02-10 | エフ．ホフマン－ラ ロシュ アーゲー | ２－（６－ニトロピリジン－３－イル）－９Ｈ－ジピリド［２，３－ｂ；３’，４’－ｄ］ピロールの製造方法 |
| CA3042260C (en) * | 2016-11-01 | 2023-10-03 | Arvinas, Inc. | Tau-protein targeting protacs and associated methods of use |
| CN110691593B (zh) | 2017-06-02 | 2023-05-02 | 富士胶片富山化学株式会社 | 脊髓小脑变性症预防或治疗剂 |
| CN110691595A (zh) | 2017-06-02 | 2020-01-14 | 富士胶片富山化学株式会社 | β-淀粉样蛋白量减少剂 |
| EP3636262A4 (en) | 2017-06-02 | 2020-06-10 | FUJIFILM Toyama Chemical Co., Ltd. | AGENT FOR PREVENTING OR TREATING ALZHEIMER-LIKE DEMENTIA |
| US20200155505A1 (en) * | 2017-06-02 | 2020-05-21 | Fujifilm Toyama Chemical Co., Ltd. | Agent for preventing or treating tauopathy |
| EP3632431A4 (en) | 2017-06-02 | 2020-06-03 | FUJIFILM Toyama Chemical Co., Ltd. | Agent for preventing or treating brain atrophy |
| EP3705121B1 (en) | 2017-10-30 | 2023-08-30 | FUJIFILM Toyama Chemical Co., Ltd. | Emopamil binding protein binding agent and use thereof |
| IL275995B2 (en) * | 2018-01-24 | 2023-09-01 | Ac Immune Sa | A new method for the preparation of imaging compound |
| US20210041447A1 (en) * | 2018-01-24 | 2021-02-11 | Ac Immune Sa | Azacarboline compounds for the detection of tau aggregates |
| EP3743423A1 (en) | 2018-01-24 | 2020-12-02 | AC Immune SA | Gamma-carboline compounds for the detection of tau aggregates |
| CN114867727B (zh) | 2019-07-17 | 2025-02-21 | 阿尔维纳斯运营股份有限公司 | Tau蛋白靶向化合物及相关使用方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1268771A (en) | 1968-03-15 | 1972-03-29 | Glaxo Lab Ltd | Azacarbazoles |
| WO2008132454A1 (en) * | 2007-04-26 | 2008-11-06 | Ge Healthcare Limited | Carbolines and their use as imaging agents |
| DK2247558T4 (da) * | 2008-02-14 | 2024-07-29 | Lilly Co Eli | Nye billeddannelsesmidler til detektering af neurologisk dysfunktion |
| US8815840B2 (en) * | 2008-12-19 | 2014-08-26 | Bristol-Myers Squibb Company | Carbazole and carboline kinase inhibitors |
| JP5976206B2 (ja) | 2012-05-22 | 2016-08-23 | イーライ リリー アンド カンパニー | 神経機能障害を検出するための造影剤 |
| US20160115162A1 (en) | 2013-05-31 | 2016-04-28 | The General Hospital Corporation | Radiosynthesis of Tau Radiopharmaceuticals |
| US9774356B2 (en) * | 2013-07-24 | 2017-09-26 | Telefonaktiebolaget Lm Ericsson (Publ) | Method and apparatus relating to reception of radio signals |
| CA2917191C (en) * | 2013-10-08 | 2021-08-10 | F. Hoffmann-La Roche Ag | Diazacarbazole derivatives as tau-pet-ligands |
| US10662193B2 (en) * | 2014-01-21 | 2020-05-26 | Ac Immune Sa | Carbazole and carboline compounds for use in the diagnosis, treatment, alleviation or prevention of disorders associated with amyloid or amyloid-like proteins |
| EP3253762B1 (en) * | 2015-02-02 | 2021-05-05 | UCB Biopharma SRL | 9h-pyrrolo-dipyridine derivatives |
-
2016
- 2016-01-29 EP EP16702121.1A patent/EP3253762B1/en active Active
- 2016-01-29 CN CN201680008314.3A patent/CN107207508B/zh active Active
- 2016-01-29 KR KR1020177024371A patent/KR102621513B1/ko active Active
- 2016-01-29 WO PCT/EP2016/051993 patent/WO2016124508A1/en not_active Ceased
- 2016-01-29 EA EA201791733A patent/EA036518B1/ru not_active IP Right Cessation
- 2016-01-29 MY MYPI2017702668A patent/MY191590A/en unknown
- 2016-01-29 JP JP2017540724A patent/JP6579670B2/ja active Active
- 2016-01-29 ES ES16702121T patent/ES2875734T3/es active Active
- 2016-01-29 AU AU2016214537A patent/AU2016214537B2/en active Active
- 2016-01-29 CA CA2973648A patent/CA2973648C/en active Active
- 2016-01-29 US US15/547,980 patent/US20180022748A1/en not_active Abandoned
- 2016-01-29 SG SG11201705727TA patent/SG11201705727TA/en unknown
- 2016-01-29 BR BR112017016311A patent/BR112017016311A2/pt not_active Application Discontinuation
- 2016-01-29 MX MX2017009505A patent/MX378155B/es unknown
- 2016-01-29 DK DK16702121.1T patent/DK3253762T3/da active
-
2017
- 2017-07-10 IL IL253381A patent/IL253381B/en active IP Right Grant
- 2017-07-27 CL CL2017001923A patent/CL2017001923A1/es unknown
-
2020
- 2020-01-22 US US16/749,537 patent/US11312716B2/en active Active
-
2022
- 2022-03-21 US US17/700,075 patent/US12006316B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| BR112017016311A2 (pt) | 2018-03-27 |
| US11312716B2 (en) | 2022-04-26 |
| US12006316B2 (en) | 2024-06-11 |
| CA2973648C (en) | 2023-09-26 |
| IL253381A0 (en) | 2017-09-28 |
| CN107207508B (zh) | 2020-02-28 |
| WO2016124508A1 (en) | 2016-08-11 |
| MX378155B (es) | 2025-03-10 |
| AU2016214537B2 (en) | 2018-05-10 |
| CN107207508A (zh) | 2017-09-26 |
| IL253381B (en) | 2020-10-29 |
| JP2018503673A (ja) | 2018-02-08 |
| US20180022748A1 (en) | 2018-01-25 |
| EA201791733A1 (ru) | 2018-01-31 |
| CL2017001923A1 (es) | 2018-02-16 |
| DK3253762T3 (da) | 2021-07-19 |
| EP3253762B1 (en) | 2021-05-05 |
| US20220213103A1 (en) | 2022-07-07 |
| KR20170113607A (ko) | 2017-10-12 |
| EP3253762A1 (en) | 2017-12-13 |
| EA036518B1 (ru) | 2020-11-18 |
| MY191590A (en) | 2022-06-30 |
| US20210047326A1 (en) | 2021-02-18 |
| KR102621513B1 (ko) | 2024-01-04 |
| ES2875734T3 (es) | 2021-11-11 |
| MX2017009505A (es) | 2017-11-02 |
| AU2016214537A1 (en) | 2017-08-03 |
| CA2973648A1 (en) | 2016-08-11 |
| JP6579670B2 (ja) | 2019-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201800826B (en) | Substituted oxopyridine derivatives | |
| DK3256580T3 (en) | Cysteinprotease | |
| IL253311A0 (en) | Green indoor cultivation | |
| IL253381B (en) | History of h9–pyrrolo–dipyridine | |
| SG11201609205WA (en) | Heterocyclyl-butanamide derivatives | |
| DK3390996T3 (en) | Trykbart tids-temperaturindikatorsystem | |
| PL3164393T3 (pl) | Pochodne flawaglin | |
| HUE050450T2 (hu) | Fluoralkil-fluorén-származékok | |
| IL248773A0 (en) | History of naphthyridinedione | |
| IL251005B (en) | Pyrido-oxazinone derivatives | |
| IL248629B (en) | Substances containing diheteroaryl conjugated to cycloalkyl and their uses | |
| AU361999S (en) | Ballustrade | |
| PL3119744T3 (pl) | Pochodne 2-cyjano-3-cyklopropylo-3-hydroksy-N-arylo-tioakryloamidu | |
| DK3294653T3 (en) | Justerbar inline-port | |
| ZA201802194B (en) | Aminoazole derivative | |
| AU5516P (en) | LEP08 Lepidosperma squamatum | |
| PT3319956T (pt) | Derivados de oxopiridina substituída | |
| AU367131S (en) | USB-charger | |
| LT3365601T (lt) | Krematoriumai | |
| AU2015212V (en) | SGIPU2-0 Scabiosa columbaria | |
| GB201508504D0 (en) | Tri-plane | |
| GB201508353D0 (en) | Sattellites | |
| GB201507770D0 (en) | Rebarmat | |
| GB201507192D0 (en) | HwBH-1 | |
| GB201505847D0 (en) | Headware |